pgµç×Ó¹ÙÍø

µÍÑõÊÊÓ¦»úÖÆÑо¿½øÕ¹

Ñõ×÷ΪÈËÀàÒÔ¼°µØÇòÉϾø´ó´ó¶¼ÉúÎïÉú´æËù±ØÐëµÄÔªËØ £¬¼ÓÈë×ÅÎïÖÊ´úлÒÔ¼°ÄÜÁ¿µÄ±¬·¢¡£ÔÚÎÒÃǵÄÈÕ³£Éú»îÖÐ £¬µÍÑõÊÇÒ»ÖÖ³£¼ûµÄÏÖÏó £¬ÀýÈç £¬ÈËÌåÄÚ²¿µÄÕý³£ÉúÀíÇé¿ö¾ÍÊÇÒ»ÖÖµÍÑõÇé¿ö¡£ÀýÈç £¬ÔÚÐÄ¡¢¸Î¡¢ÉöÄÚµÄÑõŨ¶ÈԼĪÔÚ4%-14%£»ÄÔÖеÄÑõŨ¶ÈԼĪÔÚ0.5%-7%Ö®¼ä[1]¡£ÎÒÃÇÔÚ˯¾õÆÚ¼ä¿ÉÄ᷺ܻÆð¼äЪÐÔµÄȱÑõ£»ÉË¿ÚµÄÓúºÏÒ²ÊÇÒ»ÖÖȱÑõÇé¿ö£»±ðµÄ £¬Ëæן£°ÎµÄÉý¸ß £¬´óÆøѹµÄϽµ £¬¸ßº£°ÎµØÇøµÄÑõŨ¶ÈÏà¹ØÓÚº£Æ½Ãæ»á½µµÍ £¬´Ó¶øÐÎÕûÌìÈ»µÄµÍÑõÇé¿ö¡£

¹ØÓÚ¸ßÔ­µÍÑõµÄ²»ÊÊÓ¦ £¬»á±¬·¢ÖÖÖÖ¸÷ÑùµÄ¼±¡¢ÂýÐÔ¸ßÔ­¼²²¡ £¬ÑÏÖز»ÊÊÕßÉõÖÁ»á±¬·¢¸ßÔ­·ÎË®Ö×ÒÔ¼°¸ßÔ­ÄÔË®Öס£È»¶ø £¬ÎÒ¹úÓнü250Íòƽ·½¹«ÀïµÄÃæ»ýÊÇλÓÚ¸ßÔ­Ö®ÉÏ £¬ÉúÔÚÊÀÉÏǧÍòÈË¿Ú¡£±ðµÄ £¬Ã¿ÄêÓÐ×Å´ó×ÚµÄÓοÍÈ¥Íù¸ßÔ­ÂÃÓÎ £¬ÕâЩÓοÍÖÐ £¬ÓÐÐí¶àΪ¸ßÔ­²»ÊÊÓ¦Õß¡£Òò´Ë¹ØÓÚµÍÑõÊÊÓ¦·Ö×Ó»úÖƵÄÑо¿½«ÓÐÖúÓÚ¶ÔÕâЩÈ˵ÄÌåÖʽøÐÐÅÐ¶Ï £¬²¢½øÐÐÏàÓ¦µÄÖÎÁÆ¡£±ðµÄ £¬µÍÑõ´úлͨ·Óë¶àÖÖ¼²²¡ÈçÐÄѪ¹Ü¼²²¡ £¬Ö×ÁöµÄ±¬·¢Éú³¤ÃÜÇÐÏà¹Ø[2]¡£Ëæ×ÅÈ«ÇòÈ˿ڵĿìËÙÔö³¤ £¬¸ßÔ­µÄÕ½ÂÔְλҲÓúÏÔÖØÒª¡£Òò´Ë £¬ÈËÃÇÔÚÒÑÍùµÄ20ÄêÀïͶÈëÁË´ó×ÚµÄÈËÁ¦ÎïÁ¦½øÐеÍÑõ·Ö×Ó»úÖƵÄÑо¿¡£ÏÂÃæ¾ÍÄ¿Ç°º£ÄÚÍâµÄÑо¿ÏÖ×´×öЩС½á¡£

×î³õ¹ØÓÚµÍÑõ·Ö×Ó»úÖÆÑо¿Ö÷Òª¼¯ÖÐÔÚÉúÀí¼°±íÐÍˮƽ¡£ÈËÃÇ·¢Ã÷һЩÊÀ¾Ó¸ßÔ­µÄÈËÏà¹ØÓÚº£Æ½ÃæµÄÈ˶øÑÔ £¬¸üÊÊÓ¦ÔÚ¸ßÔ­Éú»î¡£Èç £¬°²µÚ˹ÈË £¬ÎÒ¹úµÄ²Ø×åÈ˵È¡£Ñо¿ÈËԱͨ¹ý±È½Ï¸ßÔ­ÈËȺÓëµÍº£°ÎÈËȺ֮¼äµÄһϵÁÐÉúÀíÐÔ×´ £¬ÀýÈç £¬ÑªºìÂÑ°×Ũ¶È £¬ÑªÑõ±¥ºÍ¶È £¬NOŨ¶È £¬ÑªÏ¸°û±ÈÈÝµÈ £¬À´¿ª¶ËÍƶϳö¿ÉÄÜÓëµÍÑõÊÊÓ¦Ïà¹ØµÄÐÔ×´ £¬ÒÔ¼°Õâ¸öÐÔ×´¿ÉÄÜÉæ¼°µ½µÄͨ·¡£¿ÉÊÇ £¬²î±ðµÄÈËȺ¸ßÔ­ÊÊÓ¦µÄ»úÖÆÓÖËƺõÓвî±ð¡£ÀýÈç £¬ÔÚÏàͬµÄº£°ÎÌõ¼þÏ £¬²Ø×åÈ˵ÄѪºìÂÑ°×ƽ¾ùŨ¶ÈÒª±È°²µÚ˹È˵Í3.6g/dl[3]¡£×î½üµÄÑо¿ÏÔʾ £¬°²µÚ˹ÈËȺͨ¹ý·Î¶¯Âö¸ßѹÀ´¼ÓËÙѪÁ÷ºÍÔö½ø·Î²¿ÑõÆø½»»» £¬¶ø²Ø×åÈËͨ¹ýÌáÉýѪҺÖÐNOº¬Á¿À´¼ÓËÙѪҺÁ÷ËÙÒÔ¼á³ÖÑõµÄ¹©Ó¦[4]¡£±ðµÄ £¬°£Èû¶í±ÈÑǸßÔ­Ò²¾ÓסןßÔ­ÈËȺ £¬µ«ÓÉÓÚ´ËÈËȺÔÚ×é³ÉÉϱȽÏÅÓ´ó £¬¿ÉÄÜÓµÓв»Ö¹Ò»ÖÖµÍÑõÊÊÓ¦»úÖÆ¡£

Ëæ×ÅÈËÃǶÔÖÖÖÖ¼±ÂýÐÔ¸ßÔ­¼²²¡µÄÈÏʶµÄÉîÈë £¬Ñо¿ÈËÔ±¿ªÊ¼Óû¼ÖÖÖÖ¼±ÂýÐÔ¸ßÔ­¼²²¡µÄÈËÓëÕý·²È˽øÐпÉÄܵĺòÑ¡»ùÒòµÄcase-controlÑо¿¡£Ï£Íûͨ¹ý¸ßÔ­¼²²¡À´ÌáʾһЩ¿ÉÄÜÓëµÍÑõÊÊÓ¦Ïà¹ØµÄ»ùÒòÒÔ¼°Ïà¹ØµÄ·Ö×Óͨ·¡£²¢ÕÒµ½ÁËÐí¶à¿ÉÄÜÓëµÍÑõÊÊÓ¦Ïà¹ØµÄ»ùÒò £¬ÈçACE¡¢CYP11B2 £¬NO´úлÏà¹ØµÄNOS1¡¢2¡¢3»ùÒò £¬ÒÔ¼°HIF1AºÍHIF2AµÈ[5]¡£È»¶ø £¬¹ØÓÚÕâЩ»ùÒòÔÚ²î±ðµÄÎÄÕÂÖеÄÖظ´ÐÔ²¢Ç·ºÃ £¬¿ÉÄÜÔÚһƪÎÄÏ×ÖÐÖ¤Ã÷¿ÉÄÜÓëµÍÑõÊÊÓ¦Ïà¹Ø £¬¿ÉÊÇÔÚÁíÍâһƪÎÄÏ×ÖÐ £¬¿ÉÄܾÍÓëµÍÑõÊÊÓ¦Î޹ء£Òò´Ë £¬Ðí¶à»ùÒòÈÔÈ»ÓдýÓÚ½øÒ»²½µÄÑéÖ¤¡£²¢ÇÒ £¬ÈËÃǹØÓÚÕâЩ»ùÒòÖ®¼äÊÇÈçºÎÏ໥×÷ÓôӶø±¬·¢ÊÊÓ¦µÄÉúÀí״̬µÄ¾ßÌå»úÖƲ¢²»Çå³þ¡£

Ëæ×ÅÈ«»ùÒò×é¹ØÁªÆÊÎö£¨GWAS£©ÒªÁìµÄ¹ã·ºÔËÓà £¬Ñо¿ÈËÔ±Ò²½«´ËÒªÁìÓÃÓÚÁ˵ÍÑõÊÊÓ¦Ïà¹ØºòÑ¡»ùÒòµÄɸѡ¡£2010¼¸¸ö¶ÀÁ¢µÄÑо¿ÍÅ¶Ó £¬ÀûÓøßͨÁ¿·ÖÐÍÒÔ¼°Í³¼ÆѧÊֶΠ£¬É¸Ñ¡³öÁËһϵÁпÉÄÜÓë²Ø×åÈ˵ÍÑõÊÊÓ¦Ïà¹ØµÄ»ùÒò £¬Èç £¬EPAS1¡¢EGLN1¡¢PPARAµÈ £¬ÆäÖÐÒÔEPAS1ºÍEGLN1µÄÖظ´ÐÔ×îºÃ[6-9]¡£Cynthia M. Beall½áºÏѪºìÂÑ°×Ũ¶ÈµÄ±íÐÍÊý¾Ý £¬·¢Ã÷²Ø×åÈËȺÖÐÌØÓеÄEPAS1µ¥ÌåÐÍ¿ÉÄÜÓë²Ø×åÈËȺµÄµØѪºìÂÑ°×Ũ¶ÈÏà¹Ø¡£Óë´Ëͬʱ £¬BighamÀûÓÃGWASÔÚ°²µÚ˹ÈËȺÖÐÕÒµ½Ò»Ð©»ùÒò¿ÉÄÜÓë°²µÚ˹È˵ĵÍÑõÊÊÓ¦Ïà¹Ø £¬µ«²¢Î´¼ì²âµ½EPAS1ÐźŠ£¬È´·¢Ã÷HBE1¡¢EGLN1¿ÉÄÜÔÚ°²µÚ˹ÈËȺµÄ¸ßÔ­µÍÑõÊÊÓ¦ÖÐÆð×÷ÓÃ[10]¡£Õ⼸ÏîÑо¿Í¨ÔÚÒ»¶¨Ë®Æ½ÉÏ֤ʵÁËÇ°Ãæ¹ØÓÚ²Ø×åÈËȺÓë°²µÚ˹ÈËȺµÄ¸ßÔ­µÍÑõÊÊÓ¦µÄÉúÀí»úÖƱ£´æ²î±ðÕâ¸ö¼ÙÉè¡£Õ⼸ÏîÑо¿ËäÈ»´ÓÈ«»ùÒò×éˮƽɸѡ³öÁËһϵÁпÉÄÜÓë¸ßÔ­µÍÑõÊÊÓ¦Ïà¹ØµÄ»ùÒò £¬µ«ÓÉÓÚËùÓõÄSNPs¶¼Îªcommon SNPs £¬ËùÒÔ²¢²»¿ÉÈ·¶¨ÄÄЩSNPs¶Ô»ùÒò±¬·¢Ó°Ïì £¬Òò´Ë»¹ÐèÒªÆäËûÒªÁìµÄÃÖ²¹¡£Í¬Äê £¬Xin Yi et al.¶Ô50¸ö²Ø×åÈ˽øÐÐÈ«ÍâÏÔ×Ó²âÐò £¬Ï£ÍûÄÜÕÒµ½Ò»Ð©ÓëµÍÑõÊÊÓ¦Ïà¹ØµÄ»ùÒòµÄÍ»±ä[11]¡£ËäÈ»ÔÚEPAS1µÈ»ùÒòÖÐÕÒµ½ÁËеÄÍ»±ä £¬µ«ÓÉÓÚÕâЩͻ±ä¾ø´ó´ó¶¼Î»ÓÚÄÚº¬×ÓÖÐ £¬Òò´Ë¶ÔÕâЩͻ±äµÄ¹¦Ð§²»¿É×ö³öºÜºÃµÄÔ¤¼Æ¡£

×ÛºÏÒÔÍùµÄÑо¿ £¬HIF1AºÍHIF2A£¨EPAS1£©ÓëµÍÑõÊÊÓ¦µÄÏà¹ØÐÔ×î´ó¡£¼ÓÉÏÖ×ÁöÑо¿ºÍģʽ¶¯ÎïµÍÑõµ÷Àí»úÖÆÑо¿ £¬ÈËôÒѾ­¶ÔµÍÑõ¸ÐÖª¼°µ÷ÀíµÄÐźÅͨ·ÓÐÁËÒ»¶¨µÄÁ˽â¡£¼´ £¬ÔÚ³£Ñ¹³£ÑõÏ £¬HIF1AÒÔ¼°HIF2AÂѰ׻ᱻPHD2ÔÚpro402»òÕßpro564½øÐÐôÇ»ù»¯ £¬ôÇ»ù»¯ºóµÄHIF1A¡¢HIF2A»á±»VHL½øÐзºËØ»¯ £¬È»ºó¾­ÓÉÂÑ°×øÌå½µ½â¡£ÔÚµÍÑõ״̬ÏÂHIF1AºÍHIF2A²»»á±»ôÇ»ù»¯ £¬´Ó¶ø²»»á±»·ºËØ»¯ÔÙ±»ÂÑ°×øÌå½µ½â¡£Îȶ¨±£´æµÄHIF1A¼°HIF2A¾Í»áÐÐʹÆäת¼Òò×ӵĹ¦Ð§ £¬Ôö½ø±»Æäµ÷¿ØµÄ»ùÒòµÄ±í´ï¡£¿ÉÊÇHIF1AÒÔ¼°HIF2AµÄÏÂÓλùÒò¶¼ÓÐÄÄЩ £¬Æäʱ²¢²»ÊǺÜÊǵÄÇå³þ¡£

½üÁ½Äê £¬Ðí¶àÑо¿ÈËÔ±ÀûÓÃChIP-SeqµÄÊÖ¶ÎÒÔ¼°ÖÖÖÖÕý³£»òÖ×Áöϸ°ûϵ½øÐÐHIF1AÒÔ¼°HIF2AµÄÏÂÓλùÒòÑо¿ £¬»ñµÃÁ˼¸°Ù¸öºòÑ¡µÄHIF1AÒÔ¼°HIF2AµÄÏÂÓε÷¿Ø»ùÒò[12]¡£´ÓÕâЩºòÑ¡»ùÒòÁбíÖпÉÒÔ¿´³ö £¬HIF1AºÍHIF2AÓÐÒ»²¿·Öµ÷ÀíµÄ»ùÒòÊÇÏàͬµÄ £¬µ«Ò²Óи÷×ÔÌØÓеÄһЩµ÷Àí»ùÒò¡£¿ÉÊÇ¿¼Âǵ½»ùÒò±í´ïµÄ×éÖ¯ÌØÒìÐÔ £¬ÀûÓÃϸ°ûϵÀ´×öChIP-SeqÑо¿ £¬Æä½á¹û»áÓÐÒ»¶¨µÄ¾ÖÏÞÐÔ £¬¼´¿ÉÄÜ»áɥʧһ²¿·ÖÐÅÏ¢¡£±ðµÄ £¬ÔÚÖ×ÁöµÄ±¬·¢Éú³¤ÖÐ £¬ÒÔÍùÈËÃÇÈÏΪHIF1AºÍHIF2Aͨ¹ýÏ໥Эͬ´Ó¶øÔö½øÖ×ÁöµÄ±¬·¢ºÍÉú³¤ £¬¿ÉÊÇ×î½üÔ½À´Ô½¶àµÄÊÂʵ֤Ã÷ £¬Í¨¹ýHIF1AºÍHIF2A¸÷×ÔÌØÓеÄÏÂÓαí´ï»ùÒò £¬HIF1AºÍHIF2AÓÐʱ»áÌåÏÖ³öÏà·´µÄ¹¦Ð§[13]¡£

×ÛÉÏËùÊö £¬ÓÉÓÚÒªÁìºÍʵÑéÑù±¾µÄÏÞÖÆ £¬ÎÒÃǹØÓÚµÍÑõµÄ·Ö×Ó»úÖÆÁ˽âµÄÕվɺÜÉÙ¡£ÒÔºóµÄÑо¿Ó¦¸Ã´Ó²î±ðµÄ²ãÃæϵͳµÄ½øÐС£Èç £¬´ÓÈ«»ùÒò×顢ת¼×éÒÔ¼°±í¹ÛÒÅ´«×éµÈ¶à·½Ãæ·½Ãæ £¬¶ÔÏàͬµÄÑù±¾½øÐÐÉî¶ÈÍÚ¾ò£»×ۺϲî±ðµ÷¿ØˮƽµÄ½á¹ûÐγÉϵͳµÄÈÏʶ¡£

²Î¿¼ÎÄÏ×£º

1.¡¡ Ivanovic, Z., Hypoxia or in situ normoxia: The stem cell paradigm. J Cell Physiol, 2009. 219(2): p. 271-5.

2.¡¡ Lendahl, U., et al., Generating specificity and diversity in the transcriptional response to hypoxia. Nat Rev Genet, 2009. 10(12): p. 821-32.

3.¡¡ Beall, C.M., et al., Hemoglobin Concentration of High-Altitude Tibetans and Bolivian Aymara. American Journal of Physical Anthropology, 1998. 106: p. 385-400.

4.¡¡ Beall, C.M., Two routes to functional adaptation: Tibetan and Andean high-altitude natives. Proc Natl Acad Sci U S A, 2007. 104 Suppl 1: p. 8655-60.

5.¡¡ MacInnis, M.J., M.S. Koehle, and J.L. Rupert, Evidence for a genetic basis for altitude illness: 2010 update. High Alt Med Biol, 2010. 11(4): p. 349-68.

6.¡¡ Beall, C.M., et al., Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci U S A, 2010. 107(25): p. 11459-64.

7.¡¡ Simonson, T.S., et al., Genetic evidence for high-altitude adaptation in Tibet. Science, 2010. 329(5987): p. 72-5.

8.¡¡ Xu, S., et al., A genome-wide search for signals of high-altitude adaptation in Tibetans. Mol Biol Evol, 2011. 28(2): p. 1003-11.

9.¡¡ Peng, Y., et al., Genetic variations in Tibetan populations and high-altitude adaptation at the Himalayas. Mol Biol Evol, 2011. 28(2): p. 1075-81.

10. Bigham, A., et al., Identifying Signatures of Natural Selection in Tibetan and Andean Populations Using Dense Genome Scan Data. PLoS Genet, 2010. 6(9).

11. Yi, X., et al., Sequencing of 50 human exomes reveals adaptation to high altitude. Science, 2010. 329(5987): p. 75-8.

12. Schodel, J., et al., High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood, 2011. 117(23): p. e207-17.

13. Keith, B., R.S. Johnson, and M.C. Simon, HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer, 2011. 12(1): p. 9-22.

¸½¼þÏÂÔØ£º
ÍøÕ¾µØͼ